Phase 3 · NCT07232719
TRIUMPH-8
A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial
Active, not recruitingVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- TRIUMPH-8
- ClinicalTrials.gov ID
- NCT07232719
- Indication
- Obesity, Overweight
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 250
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 31 sites · United Kingdom, United States
- Study start
- 17 Nov 2025
- Primary completion
- 1 Jul 2027
- Study completion
- 1 Jul 2027
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 17 Apr 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Systolic Blood Pressure; Change from Baseline in Waist Circumference; Percent Change from Baseline in Non-High-Density Lipoprotein (HDL) Cholesterol; Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)